These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 21768792)

  • 21. Optimizing oxaliplatin-based therapy in metastatic colorectal cancer.
    Cassidy J
    Clin Adv Hematol Oncol; 2008 May; 6(5):360-1. PubMed ID: 18516025
    [No Abstract]   [Full Text] [Related]  

  • 22. [A successfully resected case of colorectal cancer with multiple liver metastases treated with FOLFIRI after failure of mFOLFOX6].
    Fukuda H; Tazawa K; Sawada S; Nagata T; Uotani H; Hirokawa S; Yamagishi F; Tsukada K
    Gan To Kagaku Ryoho; 2008 Mar; 35(3):507-9. PubMed ID: 18347406
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An increasingly common challenge: management of the complete responder with multi-focal metastatic colorectal cancer.
    Schrag D; Weiser M; Schattner M; Shia J; Akhurst T
    J Clin Oncol; 2005 Mar; 23(9):1799-802. PubMed ID: 15774773
    [No Abstract]   [Full Text] [Related]  

  • 24. Phase Ib study of drozitumab combined with first-line mFOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer.
    Rocha Lima CM; Bayraktar S; Flores AM; MacIntyre J; Montero A; Baranda JC; Wallmark J; Portera C; Raja R; Stern H; Royer-Joo S; Amler LC
    Cancer Invest; 2012 Dec; 30(10):727-31. PubMed ID: 23061802
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Conversion treatment of hepatic metastases of colon adenocarcinoma by bevacizumab and FOLFOX.
    Leite D; Kater FR
    Anticancer Drugs; 2011 Jun; 22 Suppl 2():S1-7. PubMed ID: 21768791
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer.
    Sobrero A; Ackland S; Clarke S; Perez-Carrión R; Chiara S; Gapski J; Mainwaring P; Langer B; Young S;
    Oncology; 2009; 77(2):113-9. PubMed ID: 19628950
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bevacizumab in combination with chemotherapy: first-line treatment of patients with metastatic colorectal cancer.
    Hochster HS
    Semin Oncol; 2006 Oct; 33(5 Suppl 10):S8-14. PubMed ID: 17145525
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circulating endothelial progenitors and CXCR4-positive circulating endothelial cells are predictive markers for bevacizumab.
    Matsusaka S; Mishima Y; Suenaga M; Terui Y; Kuniyoshi R; Mizunuma N; Hatake K
    Cancer; 2011 Sep; 117(17):4026-32. PubMed ID: 21858803
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Therapeutic effect of mFOLFOX6 for synchronous unresectable liver metastases from colorectal cancer].
    Chikatani K; Ishibashi K; Tajima Y; Hatano S; Amano K; Ishiguro T; Kuwabara K; Sobajima J; Ohsawa T; Okada N; Kumamoto K; Haga N; Iwama T; Ishida H
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):2211-3. PubMed ID: 22202333
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recurrent disease four years after surgery and adjuvant chemotherapy.
    Pozzo C; Barone C
    Cancer Treat Rev; 2008; 34 Suppl 2():S8-11. PubMed ID: 19101406
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fournier's gangrene as a possible side effect of bevacizumab therapy for resected colorectal cancer.
    Gamboa EO; Rehmus EH; Haller N
    Clin Colorectal Cancer; 2010 Jan; 9(1):55-8. PubMed ID: 20100690
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Short time infusion of bevacizumab in combination with 5FU-based chemotherapy as first-line therapy in a non-selective patient group with metastatic colorectal cancer.
    Dohn LH; Jensen BV; Larsen FO
    Acta Oncol; 2010 Apr; 49(3):395-6. PubMed ID: 20001495
    [No Abstract]   [Full Text] [Related]  

  • 33. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.
    Hurwitz HI; Fehrenbacher L; Hainsworth JD; Heim W; Berlin J; Holmgren E; Hambleton J; Novotny WF; Kabbinavar F
    J Clin Oncol; 2005 May; 23(15):3502-8. PubMed ID: 15908660
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Chemotherapy with bevacizumab (BV)+modified FOLFOX6 for unresectable colorectal cancer].
    Matsumoto R; Kuroda T; Yamada H; Hasegawa K; Mamiya Y; Kon A
    Gan To Kagaku Ryoho; 2009 Nov; 36(12):2207-9. PubMed ID: 20037372
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A double-blind, randomized, placebo-controlled, phase 2 study of maintenance enzastaurin with 5-fluorouracil/leucovorin plus bevacizumab after first-line therapy for metastatic colorectal cancer.
    Wolff RA; Fuchs M; Di Bartolomeo M; Hossain AM; Stoffregen C; Nicol S; Heinemann V
    Cancer; 2012 Sep; 118(17):4132-8. PubMed ID: 22213153
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Significance of CEA to predict the effect of chemotherapy with bevacizumab].
    Sasaki S; Ishimaru M; Suzuki H; Ogawa M; Sato Y
    Gan To Kagaku Ryoho; 2010 Mar; 37(3):463-7. PubMed ID: 20332684
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Modified FOLFOX6(mFOLFOX6)in metastatic colorectal carcinoma patients with poor performance status].
    Nishi T; Hamamoto Y; Uemoto J; Onodera K; Warita E; Yamanaka Y
    Gan To Kagaku Ryoho; 2012 Dec; 39(13):2557-60. PubMed ID: 23235179
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical usefulness of mitochondrial transcription factor A expression as a predictive marker in colorectal cancer patients treated with FOLFOX.
    Yoshida Y; Hasegawa J; Nezu R; Kim YK; Hirota M; Kawano K; Izumi H; Kohno K
    Cancer Sci; 2011 Mar; 102(3):578-82. PubMed ID: 21205083
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of modified FOLFOX6 for treatment of metastatic or locally advanced colorectal cancer. A single-institution outcome study.
    Matsumoto S; Nishimura T; Kanai M; Mori Y; Nagayama S; Kawamura J; Nomura A; Miyamoto S; Kitano T; Ishiguro H; Yanagihara K; Teramukai S; Sakai Y; Chiba T; Fukushima M
    Chemotherapy; 2008; 54(5):395-403. PubMed ID: 18781065
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer.
    Cohen MH; Gootenberg J; Keegan P; Pazdur R
    Oncologist; 2007 Mar; 12(3):356-61. PubMed ID: 17405901
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.